Neurodegenerative Disease Test Kit

LncRNAs are the most tissue-specific family of RNAs opening new horizons for diagnostic and therapeutic applications in the field of NDs. Identification of NeuroLINCs’ lncRNAs was performed using deep sequencing of human blood from patients with different stages of Alzheimer, patients with other dementia types, cognitively intact healthy controls and postmortem brains.

Expression levels were compared to select the brain enriched lncRNAs that are differentially expressed in the blood.

A total of 7494 lncRNAs, including 1816 novel lncRNAs never previously described, were identified and those which correlate with the relevant biomarkers of Alzheimer brain pathology (CSF Abeta or Tau) and neurodegeneration (volumetric scores of mediotemporal and hippocampal atrophy) are included into NeuroLINCs panel.

Features and benefits

FIRST INCLASS TEST

for the measurement of brain enriched IncRNAs in peripheral blood.

FIRST TEST OF BLOOD LNCRNA BIOMARKERS

for diagnostic of MCI, early Alzheimer and other dementia types.

INVESTIGATION OF A NOVELCLASS

of therapeutic targets.

PROPRIETARY LIST

of brain enriched IncRNAs.

Simplified workflow

Non-invasively collected samples to investigate lncRNAs.

PAXgene, plasma, brain tissue, PBMCs already validated.

Excellent analytical performance with high reproducibility of the results.

High sensitivity with 5930 lncRNAs detected in PAXgene and 3166 in Plasma over a total of 7494 lncRNAs.

OPTIMIZE YOUR BIOMARKER PROJECTS AND DEVELOPMENT PROGRAMS

From concept to regulatory qualification, with significant experience in each step, we provide steadfast support across diverse areas